New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin, human, recombinant dna origin 100 [iu] - solution for injection - 100 iu/ml - active: insulin, human, recombinant dna origin 100 [iu] excipient: glycerol hydrochloric acid as 10% solution for ph adjustment metacresol sodium hydroxide as 10% solution for ph adjustment water for injection - humulin is indicated for the treatment of insulin-requiring diabetes mellitus.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [usp'u] in 1 ml - important: know your insulin. do not change the type of insulin you use unless told to do so by your healthcare provider. the amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin. make sure that you know the type and strength of insulin that is prescribed for you. read the patient information leaflet that comes with novolin 70/30 before you start taking it and each time you get a refill. there may be new information. this leaflet does not take the place of talking with your healthcare provider about your diabetes or your treatment. make sure you know how to manage your diabetes. ask your healthcare provider if you have any questions about managing your diabetes. what is novolin 70/30? novolin 70/30 is a man-made insulin (recombinant dna origin) which is a mixture of 70% nph, human insulin isophane suspension and 30% regular, human insulin injection that is structurally identical to the insulin produced by the human pancrea

United States - English - NLM (National Library of Medicine)

tya pharmaceuticals - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [usp'u] in 1 ml - important: do not change the type of insulin you use unless told to do so by your healthcare provider. the amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin. know your insulin. make sure that you know the type and strength of insulin that is prescribed for you. read the patient information leaflet that comes with novolin 70/30 before you start taking it and each time you get a refill. there may be new information. this leaflet does not take the place of talking with your healthcare provider about your diabetes or your treatment. make sure you know how to manage your diabetes. ask your healthcare provider if you have any questions about managing your diabetes. ® what is novolin 70/30? ® novolin 70/30 is a man-made insulin (recombinant dna origin) which is a mixture of 70% nph, human insulin isophane suspension and 30% regular, human in

United States - English - NLM (National Library of Medicine)

tya pharmaceuticals - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - important: . do not change the type of insulin you use unless told to do so by your healthcare provider. the amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin. know your insulin make sure that you know the type and strength of insulin that is prescribed for you. read the patient information leaflet that comes with novolin n before you start taking it and each time you get a refill. there may be new information. this leaflet does not take the place of talking with your healthcare provider about your diabetes or your treatment. make sure you know how to manage your diabetes. ask your healthcare provider if you have any questions about managing your diabetes. ® what is novolin n? ® novolin n is a man-made insulin (recombinant dna origin) nph, human insulin isophane suspension that is structurally identical to the insulin produced by the

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: sodium hydroxide; glycerol; metacresol; zinc oxide; phenol; dibasic sodium phosphate heptahydrate; protamine sulfate; hydrochloric acid; water for injections - this product accepted for registration as 'currently supplied' at the time of commencement of the act. humulin is indicated for the treatment of insulin-dependent diabetic patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

maxx pharma pty ltd - insulin glargine, quantity: 100 u/ml - injection, solution - excipient ingredients: sodium hydroxide; glycerol; water for injections; hydrochloric acid; metacresol; zinc chloride - insulin glargine is an insulin analogue indicated for once-daily subcutaneous administration in the treatment of type 1 diabetes mellitus in adults and children and type 2 diabetes mellitus in adults who require insulin for the control of hyperglycaemia.

Philippines - English - FDA (Food And Drug Administration)

pacific healthcare phils inc - isophane human insulin 70/30 - suspension for injection sc recombinant dna origin - 100 iu/ml

United States - English - NLM (National Library of Medicine)

tya pharmaceuticals - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - novolin r is indicated to improve glycemic control in adults and children with diabetes mellitus. novolin r is contraindicated: pregnancy category b: all pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. this background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good glycemic control. it is essential for patients with diabetes or a history of gestational diabetes to maintain good glycemic control before conception and throughout pregnancy. insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline after delivery. careful monitoring of glucose control is important during pregnancy in patients with diabetes. therefore, women should be advised to tell their healthcare provider if they intend to become, or if they become, pregnant while taking novolin r. no reproductive toxicity studies have been performed with novolin r. it 

Canada - English - Health Canada

sanofi-aventis canada inc - insulin glulisine (recombinant dna origin) - solution - 100unit - insulin glulisine (recombinant dna origin) 100unit - insulins

Canada - English - Health Canada

sanofi-aventis canada inc - insulin glulisine (recombinant dna origin) - solution - 100unit - insulin glulisine (recombinant dna origin) 100unit - insulins